Corcept Therapeutics
CA - Redwood City
Biotechnology1 H-1B visas (FY2023)Focus: Small Molecules
Corcept Therapeutics is a life sciences company focused on Small Molecules.
OncologyEndocrinologyInfectious DiseasesNeurologyGastroenterology
Employees
201-500
Open Jobs
0
Products & Portfolio (1)
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT05320146A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
N/ARetrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
HypercortisolismClinical Trials (1)
NCT03379363Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
N/ANo intervention
Cushing's SyndromeClinical Trials (1)
NCT02663609Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
N/ABiomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
Cushing's SyndromeClinical Trials (1)
NCT02922257Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
N/ACushing's syndrome confirmation
Cushing's SyndromeClinical Trials (1)
NCT00796783A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
N/AStudy of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOME
Resistant HypertensionClinical Trials (1)
NCT06829537Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
N/ARelacorilant
HealthyClinical Trials (1)
NCT04795479T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
Phase 1Dabigatran Etexilate
Cushing SyndromeClinical Trials (1)
NCT05347979Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
Phase 1Relacorilant 350mg
HealthyClinical Trials (1)
NCT03512548Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites
Phase 1CORT125329 lipid capsule formulation
HealthyClinical Trials (1)
NCT04672512Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants
Phase 1CORT118335 Oral
HealthyClinical Trials (1)
NCT03878264Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
Phase 1Miricorilant 300 mg tablets
HealthyClinical Trials (1)
NCT04672499Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants
Phase 1CORT125236
HealthyClinical Trials (1)
NCT05003713Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants
Phase 1Miricorilant
Antipsychotic Induced Weight GainClinical Trials (1)
NCT05712265Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
Phase 1Mifepristone
HealthyClinical Trials (1)
NCT03258372Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
Phase 1CORT125134
HealthyClinical Trials (1)
NCT06094712A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
Phase 1CORT125281, 40mg, fasted
HealthyClinical Trials (1)
NCT03335956CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
Phase 1Miricorilant Treatment A
HealthyClinical Trials (1)
NCT07240116Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects
Phase 1Relacorilant Fasted
HealthyClinical Trials (1)
NCT03442621Relacorilant Food Effect Study in Healthy Subjects
Phase 1CORT113176
Healthy AdultsClinical Trials (1)
NCT04994743Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants
Phase 1[14C]-CORT125134
HealthyClinical Trials (1)
NCT03067376A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body
Phase 1CORT118335, 25 mg
HealthyClinical Trials (1)
NCT03315338First-in-human Study in Healthy Subjects
Phase 1Miricorilant
Nonalcoholic Steatohepatitis (NASH)Clinical Trials (1)
NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Phase 1Relacorilant
Hepatic ImpairmentClinical Trials (1)
NCT06094725A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Phase 1CORT125134 150 mg
HealthyClinical Trials (1)
NCT06094790A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
Phase 1Dazucorilant
Healthy AdultsClinical Trials (1)
NCT06495944Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
Phase 114C-CORT125281
HealthyClinical Trials (1)
NCT03877952Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants
Phase 1Olanzapine
Antipsychotic-induced Weight GainClinical Trials (1)
NCT03877562The Effect of CORT118335 on Olanzapine-Induced Weight Gain
Phase 1Mifepristone and Eribulin in combination
Breast CancerClinical Trials (1)
NCT02014337Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1[14C]-CORT113176
HealthyClinical Trials (1)
NCT04990310Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants
Phase 1CORT125134
HealthyClinical Trials (1)
NCT03508635CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
Phase 1Mifepristone 300 MG
Drug Interaction PotentiationClinical Trials (1)
NCT03259542Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
Phase 1Relacorilant
Adrenocortical CarcinomaClinical Trials (1)
NCT04373265Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Phase 1Enzalutamide
Prostate CancerClinical Trials (1)
NCT03674814Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Phase 1Dazucorilant
Hepatic ImpairmentClinical Trials (1)
NCT06928779Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
Phase 1Miricorilant
Non-alcoholic Steatohepatitis (NASH)Clinical Trials (1)
NCT05553470Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
Phase 1mifepristone + fluvastatin
Healthy SubjectsClinical Trials (1)
NCT00752843A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
Phase 1Miricorilant 150 mg
Nonalcoholic Steatohepatitis (NASH)Clinical Trials (1)
NCT05117489A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Phase 1Relacorilant under fasted conditions
HealthyClinical Trials (1)
NCT06094738A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
Phase 1Relacorilant
HealthyClinical Trials (1)
NCT03540836A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
Phase 1Risperidone
HealthyClinical Trials (1)
NCT00698022A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
Phase 1CORT113176 Lipid Capsule Formulation
Healthy AdultsClinical Trials (1)
NCT04249323Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
Phase 1Midazolam hydrochloride
HealthyClinical Trials (1)
NCT03457597Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
Phase 1Phase 1/2
Clinical Trials (1)
NCT03437941Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Phase 1/2Nenocorilant 200 mg
NeoplasmsClinical Trials (1)
NCT07276373Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Phase 1/2Relacorilant with nab-paclitaxel
Solid TumorsClinical Trials (1)
NCT02762981Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Phase 1/2Dazucorilant 300 mg
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT05407324Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Phase 2Mifepristone
Major Depressive DisorderClinical Trials (1)
NCT05217758RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma
Phase 2Relacorilant 150 mg once daily
AdenocarcinomaClinical Trials (1)
NCT07259317Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 2Relacorilant
Recurrent Ovarian CancerClinical Trials (1)
NCT03776812Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 1 approved product, 76 clinical trials
Top TAs: Oncology, Endocrinology, Infectious Diseases
H-1B (2023): 1 approval
Portfolio Health
Peak1 (100%)
1 total products
Therapeutic Area Focus
Oncology
13 pipeline
Endocrinology
12 pipeline
Infectious Diseases
7 pipeline
Neurology
3 pipeline
Gastroenterology
3 pipeline
Metabolic Diseases
2 pipeline
Women's Health
1 marketed
Nephrology
1 pipeline
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub